Drug Profile
Cinacalcet - Amgen/Kirin Holdings Company/Takeda
Alternative Names: 226256-56-0; AMG-073; Cinacalcet HCL; Cinacalcet hydrochloride; KRN-1493; Mimpara; NPS-1493; Regpara; SensiparLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator NPS Pharmaceuticals
- Developer Amgen; Kirin Holdings Company
- Class Antihypercalcaemics; Naphthalenes; Small molecules
- Mechanism of Action Calcium channel agonists; Parathyroid hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypercalcaemia; Primary hyperparathyroidism; Secondary hyperparathyroidism
- No development reported Cardiovascular disorders
Most Recent Events
- 30 Jun 2023 Launched for Primary hyperparathyroidism in Hong Kong (PO) (Kyowa Kirin pipeline, August 2023)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Hypercalcaemia(In volunteers) in USA (PO, Capsule)
- 28 Dec 2020 No recent reports of development identified for phase-I development in Secondary-hyperparathyroidism(In volunteers) in USA (PO, Capsule)